Loading…

Serum levels of monocyte chemoattractant protein-1 and all-cause and cardiovascular mortality among patients with coronary artery disease

Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine at multiple phases of atherosclerosis in animals, but human studies are few and inconsistent. The aim of this study is to investigate the association of serum MCP-1 with all-cause and cardiovascular disease (CVD) mortality among co...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-03, Vol.10 (3), p.e0120633-e0120633
Main Authors: Ding, Ding, Su, Dongfang, Li, Xinrui, Li, Zhongxia, Wang, Yujie, Qiu, Jian, Lin, Puqing, Zhang, Yuan, Guo, Pi, Xia, Min, Li, Dan, Yang, Yan, Hu, Gang, Ling, Wenhua
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine at multiple phases of atherosclerosis in animals, but human studies are few and inconsistent. The aim of this study is to investigate the association of serum MCP-1 with all-cause and cardiovascular disease (CVD) mortality among coronary artery disease (CAD) patients and determine whether this biomarker can add secondary prognostic value to standard risk predictors. MCP-1 was measured at baseline in 1411 CAD patients who were 40-85 years of age. Cox proportional hazards regression models were used to estimate the association of MCP-1 levels with death risk. During a median follow-up of 3.3 years, 117 deaths were recorded, 88 of which were due to CVD. The multivariable-adjusted hazard ratios across tertiles of MCP-1 were 1.51 (95% confidence intervals [CI] 0.89-2.58), 1.00, and 2.11 (95% CI 1.31-3.40) for all-cause mortality, and 1.50 (95% CI 0.80-2.81), 1.00, and 2.21 (95% CI 1.27-3.87) for CVD mortality. The addition of serum MCP-1 to the fully adjusted model increased the C-index by 0.009 (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0120633